AQST
Aquestive Therapeutics, Inc.
Price Chart
Latest Quote
$3.94
-0.20 (-4.72%)
Current Price
| Previous Close | $4.14 |
| Open | $4.14 |
| Day High | $4.16 |
| Day Low | $3.94 |
| Volume | 959,001 |
Stock Information
| Shares Outstanding | 125.45M |
| Total Debt | $43.58M |
| Cash Equivalents | $110.73M |
| Revenue | $50.27M |
| Net Income | $-68.91M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $493.02M |
| EPS (TTM) | $-0.61 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $425.87M |
| Sales | $50.27M |
| Income | $-68.91M |
| Book/sh | $-0.27 |
| Cash/sh | $0.88 |
| Employees | 147 |
Financial Ratios
| Quick Ratio | 3.70 |
| Current Ratio | 4.10 |
Returns & Margins
| ROA | -28.71% |
| Gross Margin | 63.45% |
| Operating Margin | -29.10% |
| Profit Margin | -137.08% |
Ownership
| Insider Ownership | 3.10% |
| Institutional Ownership | 60.59% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -8.73 |
| P/S | 9.81 |
| P/B | -14.34 |
Analyst Data
| Recommendation | none |
| Target Price | $8.89 |
Technical Indicators
| SMA20 | $4.14 |
| SMA50 | $4.15 |
| SMA200 | $4.88 |
| RSI | 37.76 |
| ATR | 0.1540 |
| Shares Float | 114.54M |
| Short Float | 12.55% |
| Short Ratio | 9.35 |
| Volatility | 1.45 |
| Rel Volume | 0.65 |
Performance History
| Week | -2.24% |
| Month | -7.09% |
| Quarter | -6.87% |
| 6 Months | -36.10% |
| YTD | -39.07% |
| Year | +15.25% |
| 3 Years | +70.13% |
| 5 Years | +5.93% |
| 10 Years | -75.51% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $3.93 | 1,228,500 |
| 2026-06-04 | $4.14 | 1,937,700 |
| 2026-06-03 | $4.03 | 1,698,400 |
| 2026-06-02 | $3.93 | 1,972,100 |
| 2026-06-01 | $4.00 | 1,413,000 |
| 2026-05-29 | $4.02 | 1,322,200 |
| 2026-05-28 | $4.02 | 1,415,900 |
| 2026-05-27 | $4.00 | 1,388,500 |
| 2026-05-26 | $4.08 | 1,051,400 |
| 2026-05-22 | $4.12 | 892,800 |
| 2026-05-21 | $4.23 | 1,349,900 |
| 2026-05-20 | $4.17 | 1,203,800 |
| 2026-05-19 | $4.09 | 1,557,600 |
| 2026-05-18 | $4.14 | 2,688,500 |
| 2026-05-15 | $4.17 | 3,419,800 |
| 2026-05-14 | $4.73 | 5,849,700 |
| 2026-05-13 | $4.13 | 2,477,300 |
| 2026-05-12 | $4.16 | 1,401,900 |
| 2026-05-11 | $4.34 | 1,387,500 |
| 2026-05-08 | $4.32 | 1,893,100 |
| 2026-05-07 | $4.23 | 1,307,300 |
| 2026-05-06 | $4.23 | 1,628,300 |
About Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older. The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
đ° Latest News
The Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Simply Wall St. âĸ 2026-05-15T12:56:37Z
Aquestive Therapeutics Inc (AQST) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
GuruFocus.com âĸ 2026-05-14T23:03:25ZAquestive Therapeutics Q1 Earnings Call Highlights
MarketBeat âĸ 2026-05-14T14:07:38Z
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
Zacks âĸ 2026-05-13T22:00:03Z
Aquestive Therapeutics (AQST) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-13T21:15:02Z
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga âĸ 2026-05-13T21:06:19Z
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-07T21:55:04Z
Will Journey Medical Corporation (DERM) Report Negative Q1 Earnings? What You Should Know
Zacks âĸ 2026-05-06T14:00:04Z
Will Aquestive Therapeutics (AQST) Report Negative Q1 Earnings? What You Should Know
Zacks âĸ 2026-05-04T14:00:10Z
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Zacks âĸ 2026-04-09T13:00:04Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $18,555,000 | $17,872,000 | $20,831,000 | $19,386,000 |
| Cost Of Revenue | $18,555,000 | $17,872,000 | $20,831,000 | $19,386,000 |
| Total Revenue | $44,545,000 | $57,561,000 | $50,583,000 | $47,680,000 |
| Operating Revenue | $44,545,000 | $57,561,000 | $50,583,000 | $47,680,000 |
| Expenses | ||||
| Interest Expense | $17,100,000 | $16,817,000 | $7,462,000 | $12,443,000 |
| Total Expenses | $115,596,000 | $88,332,000 | $65,685,000 | $89,746,000 |
| Net Non Operating Interest Income Expense | $-12,733,000 | $-13,380,000 | $8,859,000 | $-12,344,000 |
| Interest Expense Non Operating | $17,100,000 | $16,817,000 | $7,462,000 | $12,443,000 |
| Operating Expense | $97,041,000 | $70,460,000 | $44,854,000 | $70,360,000 |
| Other Income Expense | - | - | $-1,382,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-83,784,000 | $-44,137,000 | $-7,870,000 | $-54,410,000 |
| Net Interest Income | $-12,733,000 | $-13,380,000 | $8,859,000 | $-12,344,000 |
| Interest Income | $4,367,000 | $3,437,000 | $16,321,000 | $99,000 |
| Normalized Income | $-83,784,000 | $-44,137,000 | $-6,778,220 | $-54,410,000 |
| Net Income From Continuing And Discontinued Operation | $-83,784,000 | $-44,137,000 | $-7,870,000 | $-54,410,000 |
| Total Operating Income As Reported | $-71,051,000 | $-30,771,000 | $-15,102,000 | $-42,066,000 |
| Net Income Common Stockholders | $-83,784,000 | $-44,137,000 | $-7,870,000 | $-54,410,000 |
| Net Income | $-83,784,000 | $-44,137,000 | $-7,870,000 | $-54,410,000 |
| Net Income Including Noncontrolling Interests | $-83,784,000 | $-44,137,000 | $-7,870,000 | $-54,410,000 |
| Net Income Continuous Operations | $-83,784,000 | $-44,137,000 | $-7,870,000 | $-54,410,000 |
| Pretax Income | $-83,784,000 | $-44,151,000 | $-7,625,000 | $-54,410,000 |
| Interest Income Non Operating | $4,367,000 | $3,437,000 | $16,321,000 | $99,000 |
| Operating Income | $-71,051,000 | $-30,771,000 | $-15,102,000 | $-42,066,000 |
| Gross Profit | $25,990,000 | $39,689,000 | $29,752,000 | $28,294,000 |
| Special Income Charges | - | $0 | $-1,382,000 | $0 |
| Per Share | ||||
| Diluted EPS | - | $-0.51 | $-0.13 | $-1.12 |
| Basic EPS | - | $-0.51 | $-0.13 | $-1.12 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $-290,220 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-66,136,000 | $-26,616,000 | $2,564,000 | $-39,580,000 |
| Reconciled Depreciation | $548,000 | $718,000 | $1,345,000 | $2,387,000 |
| EBITDA (Bullshit earnings) | $-66,136,000 | $-26,616,000 | $1,182,000 | $-39,580,000 |
| EBIT | $-66,684,000 | $-27,334,000 | $-163,000 | $-41,967,000 |
| Diluted NI Availto Com Stockholders | $-83,784,000 | $-44,137,000 | $-7,870,000 | $-54,410,000 |
| Tax Provision | $0 | $-14,000 | $245,000 | $0 |
| Research And Development | $17,192,000 | $20,280,000 | $13,104,000 | $17,481,000 |
| Selling General And Administration | $79,849,000 | $50,180,000 | $31,750,000 | $52,879,000 |
| Total Unusual Items | - | $0 | $-1,382,000 | $0 |
| Total Unusual Items Excluding Goodwill | - | $0 | $-1,382,000 | $0 |
| Diluted Average Shares | - | $86,726,211 | $61,255,864 | $48,734,377 |
| Basic Average Shares | - | $86,726,211 | $61,255,864 | $48,734,377 |
| Other Special Charges | - | - | $1,382,000 | - |
Fetched: 2026-05-26
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-33,662,000 | $-60,156,000 | $-107,765,000 | $-119,989,000 |
| Total Assets | $160,425,000 | $101,424,000 | $57,418,000 | $57,070,000 |
| Total Non Current Assets | $11,156,000 | $13,204,000 | $16,452,000 | $17,182,000 |
| Other Non Current Assets | $642,000 | $1,223,000 | $1,438,000 | $1,451,000 |
| Non Current Accounts Receivable | $2,000,000 | $3,000,000 | $4,000,000 | $5,000,000 |
| Current Assets | $149,269,000 | $88,220,000 | $40,966,000 | $39,888,000 |
| Other Current Assets | $4,168,000 | $3,286,000 | $1,854,000 | $2,131,000 |
| Inventory | $6,169,000 | $6,044,000 | $6,769,000 | $5,780,000 |
| Receivables | $17,763,000 | $7,344,000 | $8,471,000 | $4,704,000 |
| Receivables Adjustments Allowances | $-582,000 | $-48,000 | $-14,000 | $-709,000 |
| Other Receivables | $10,332,000 | $2,473,000 | $2,915,000 | $2,139,000 |
| Accounts Receivable | $8,013,000 | $4,919,000 | $5,570,000 | $3,274,000 |
| Cash Cash Equivalents And Short Term Investments | $121,169,000 | $71,546,000 | $23,872,000 | $27,273,000 |
| Cash And Cash Equivalents | $121,169,000 | $71,546,000 | $23,872,000 | $27,273,000 |
| Goodwill And Other Intangible Assets | - | $0 | $1,278,000 | $1,435,000 |
| Other Intangible Assets | - | - | $1,278,000 | $1,435,000 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $42,481,000 | $38,004,000 | $33,319,000 | $57,488,000 |
| Long Term Debt And Capital Lease Obligation | $31,856,000 | $37,468,000 | $32,907,000 | $38,533,000 |
| Long Term Debt | $27,519,000 | $32,500,000 | $27,508,000 | $33,448,000 |
| Current Debt And Capital Lease Obligation | $10,625,000 | $536,000 | $412,000 | $18,955,000 |
| Current Debt | $9,994,000 | $26,000 | $22,000 | $18,700,000 |
| Other Current Borrowings | $9,994,000 | $26,000 | $22,000 | $18,700,000 |
| Net Debt | - | - | $3,658,000 | $24,875,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $194,087,000 | $161,580,000 | $163,905,000 | $175,624,000 |
| Total Non Current Liabilities Net Minority Interest | $146,479,000 | $142,715,000 | $145,597,000 | $136,096,000 |
| Other Non Current Liabilities | $33,210,000 | $22,524,000 | $16,777,000 | $2,034,000 |
| Liabilities Heldfor Sale Non Current | $62,023,000 | $62,718,000 | $63,568,000 | $64,112,000 |
| Non Current Deferred Liabilities | $19,390,000 | $20,005,000 | $32,345,000 | $31,417,000 |
| Current Liabilities | $47,608,000 | $18,865,000 | $18,308,000 | $39,528,000 |
| Other Current Liabilities | $1,000,000 | $1,087,000 | $922,000 | $1,147,000 |
| Current Deferred Liabilities | $1,092,000 | $1,048,000 | $1,551,000 | $1,513,000 |
| Payables And Accrued Expenses | $31,184,000 | $11,462,000 | $11,221,000 | $11,524,000 |
| Interest Payable | $17,000 | $17,000 | $1,013,000 | $183,000 |
| Payables | $30,211,000 | $10,652,000 | $9,263,000 | $10,268,000 |
| Total Tax Payable | $349,000 | $365,000 | $337,000 | $322,000 |
| Accounts Payable | $29,862,000 | $10,287,000 | $8,926,000 | $9,946,000 |
| Equity | ||||
| Common Stock Equity | $-33,662,000 | $-60,156,000 | $-106,487,000 | $-118,554,000 |
| Total Equity Gross Minority Interest | $-33,662,000 | $-60,156,000 | $-106,487,000 | $-118,554,000 |
| Stockholders Equity | $-33,662,000 | $-60,156,000 | $-106,487,000 | $-118,554,000 |
| Retained Earnings | $-446,998,000 | $-363,214,000 | $-319,077,000 | $-311,207,000 |
| Other | ||||
| Ordinary Shares Number | $122,044,299 | $91,413,742 | $68,533,085 | $54,827,734 |
| Share Issued | $122,044,299 | $91,413,742 | $68,533,085 | $54,827,734 |
| Tangible Book Value | $-33,662,000 | $-60,156,000 | $-107,765,000 | $-119,989,000 |
| Invested Capital | $3,851,000 | $-27,630,000 | $-78,957,000 | $-66,406,000 |
| Working Capital | $101,661,000 | $69,355,000 | $22,658,000 | $360,000 |
| Capital Lease Obligations | $4,968,000 | $5,478,000 | $5,789,000 | $5,340,000 |
| Total Capitalization | $-6,143,000 | $-27,656,000 | $-78,979,000 | $-85,106,000 |
| Additional Paid In Capital | $413,214,000 | $302,967,000 | $212,521,000 | $192,598,000 |
| Capital Stock | $122,000 | $91,000 | $69,000 | $55,000 |
| Common Stock | $122,000 | $91,000 | $69,000 | $55,000 |
| Non Current Deferred Revenue | $19,390,000 | $20,005,000 | $32,345,000 | $31,417,000 |
| Long Term Capital Lease Obligation | $4,337,000 | $4,968,000 | $5,399,000 | $5,085,000 |
| Current Deferred Revenue | $1,092,000 | $1,048,000 | $1,551,000 | $1,513,000 |
| Current Capital Lease Obligation | $631,000 | $510,000 | $390,000 | $255,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $3,707,000 | $4,732,000 | $4,202,000 | $6,389,000 |
| Current Accrued Expenses | $973,000 | $810,000 | $1,958,000 | $1,256,000 |
| Net PPE | $8,514,000 | $8,981,000 | $9,736,000 | $9,296,000 |
| Accumulated Depreciation | $-44,021,000 | $-43,501,000 | $-42,884,000 | $-41,963,000 |
| Gross PPE | $52,535,000 | $52,482,000 | $52,620,000 | $51,259,000 |
| Leases | $21,419,000 | $21,419,000 | $21,386,000 | $21,375,000 |
| Construction In Progress | $2,203,000 | $2,110,000 | $2,033,000 | $1,467,000 |
| Other Properties | $4,621,000 | $5,182,000 | $5,557,000 | $5,211,000 |
| Machinery Furniture Equipment | $24,292,000 | $23,771,000 | $23,644,000 | $23,206,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Inventories | $2,362,000 | $2,135,000 | $3,028,000 | $2,914,000 |
| Finished Goods | $664,000 | $643,000 | $1,623,000 | $967,000 |
| Raw Materials | $3,143,000 | $3,266,000 | $2,118,000 | $1,899,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-05-26
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-52,994,000 | $-35,918,000 | $-7,375,000 | $-12,343,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-52,432,000 | $-35,759,000 | $-6,380,000 | $-9,819,000 |
| Cash Flow From Continuing Operating Activities | $-52,432,000 | $-35,759,000 | $-6,380,000 | $-9,819,000 |
| Operating Gains Losses | - | - | $1,029,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-562,000 | $-159,000 | $-995,000 | $-2,524,000 |
| Investing Cash Flow | $-562,000 | $-159,000 | $-995,000 | $-2,524,000 |
| Cash Flow From Continuing Investing Activities | $-562,000 | $-159,000 | $-995,000 | $-2,524,000 |
| Capital Expenditure Reported | $-562,000 | $-159,000 | $-995,000 | $-1,024,000 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $100,654,000 | $83,757,000 | $8,912,000 | $13,586,000 |
| Financing Cash Flow | $102,617,000 | $83,592,000 | $3,974,000 | $11,592,000 |
| Cash Flow From Continuing Financing Activities | $102,617,000 | $83,592,000 | $3,974,000 | $11,592,000 |
| Net Other Financing Charges | $-821,000 | $-1,106,000 | $9,202,000 | $-3,000 |
| Net Common Stock Issuance | $100,654,000 | $83,757,000 | $8,912,000 | $13,586,000 |
| Common Stock Issuance | $100,654,000 | $83,757,000 | $8,912,000 | $13,586,000 |
| Other | ||||
| Repayment Of Debt | $-26,000 | $-23,000 | $-53,631,000 | $-2,025,000 |
| Interest Paid Supplemental Data | $6,098,000 | $7,097,000 | $4,602,000 | $6,436,000 |
| Income Tax Paid Supplemental Data | $0 | $305,000 | $0 | - |
| End Cash Position | $121,169,000 | $71,546,000 | $23,872,000 | $27,273,000 |
| Beginning Cash Position | $71,546,000 | $23,872,000 | $27,273,000 | $28,024,000 |
| Changes In Cash | $49,623,000 | $47,674,000 | $-3,401,000 | $-751,000 |
| Proceeds From Stock Option Exercised | $2,810,000 | $964,000 | $8,347,000 | $34,000 |
| Net Issuance Payments Of Debt | $-26,000 | $-23,000 | $-22,487,000 | $-2,025,000 |
| Net Long Term Debt Issuance | $-26,000 | $-23,000 | $-22,487,000 | $-2,025,000 |
| Long Term Debt Payments | $-26,000 | $-23,000 | $-53,631,000 | $-2,025,000 |
| Change In Working Capital | $12,184,000 | $-9,957,000 | $-5,341,000 | $31,977,000 |
| Change In Other Working Capital | $-571,000 | $-12,843,000 | $966,000 | $25,043,000 |
| Change In Payables And Accrued Expense | $22,555,000 | $1,290,000 | $-3,535,000 | $-74,000 |
| Change In Accrued Expense | $3,032,000 | $-1,492,000 | $-2,515,000 | $-2,382,000 |
| Change In Payable | $19,523,000 | $2,782,000 | $-1,020,000 | $2,308,000 |
| Change In Account Payable | $19,523,000 | $2,782,000 | $-1,020,000 | $1,633,000 |
| Change In Prepaid Assets | $698,000 | $-223,000 | $1,290,000 | $1,399,000 |
| Change In Inventory | $-126,000 | $725,000 | $-989,000 | $-1,743,000 |
| Change In Receivables | $-10,372,000 | $1,094,000 | $-3,073,000 | $7,352,000 |
| Other Non Cash Items | $10,996,000 | $10,518,000 | $1,768,000 | $5,846,000 |
| Stock Based Compensation | $7,624,000 | $7,099,000 | $2,689,000 | $4,381,000 |
| Depreciation Amortization Depletion | $548,000 | $718,000 | $1,345,000 | $2,387,000 |
| Depreciation And Amortization | $548,000 | $718,000 | $1,345,000 | $2,387,000 |
| Depreciation | $548,000 | $640,000 | $1,345,000 | $2,387,000 |
| Net Income From Continuing Operations | $-83,784,000 | $-44,137,000 | $-7,870,000 | $-54,410,000 |
| Issuance Of Debt | - | $0 | $31,144,000 | $0 |
| Long Term Debt Issuance | - | $0 | $31,144,000 | $0 |
| Amortization Cash Flow | - | $78,000 | - | - |
| Amortization Of Intangibles | - | $78,000 | - | - |
| Net Intangibles Purchase And Sale | - | - | $0 | $-1,500,000 |
| Purchase Of Intangibles | - | - | $0 | $-1,500,000 |
| Change In Other Current Liabilities | - | - | - | $675,000 |
Fetched: 2026-05-26